Ensartinib treatment for REV1-ALK/EML4-ALK complex ALK fusion lung adenocarcinoma: a case report

ZHANG Chang-gong

PDF(686 KB)
PDF(686 KB)
Chinese Journal of New Drugs ›› 2025, Vol. 34 ›› Issue (5) : 490-493. DOI: 10.20251/j.cnki.1003-3734.2025.05.007

Ensartinib treatment for REV1-ALK/EML4-ALK complex ALK fusion lung adenocarcinoma: a case report

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

QR code of this article

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2025, 34(5): 490-493 https://doi.org/10.20251/j.cnki.1003-3734.2025.05.007

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(686 KB)

Accesses

Citation

Detail
Sections
Recommended
Total:
Copyright © Chinese Journal of New Drugs, All Rights Reserved.
Tel: 010-52722697 | 010-52723707
　 Powered by Beijing Magtech Co., Ltd.

/

〈 〉